vs

Side-by-side financial comparison of Caesarstone Ltd. (CSTE) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.

Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $94.4M, roughly 1.7× Caesarstone Ltd.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -93.1%, a 164.3% gap on every dollar of revenue. Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-47.1M).

Caesarstone Ltd., is a publicly traded company that engages in the production and marketing of quartz, porcelain, mineral and advanced fusion surfaces used for kitchen countertops, vanity tops, flooring, wall cladding and general interior design. The company was founded in 1987 and is traded on the NASDAQ in New York (CSTE). Headquarters are located in Kibbutz Sdot Yam in Israel. Production facilities are in Israel and India with third party manufactured product sourced from factories in the ...

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.

CSTE vs STOK — Head-to-Head

Bigger by revenue
STOK
STOK
1.7× larger
STOK
$158.6M
$94.4M
CSTE
Higher net margin
STOK
STOK
164.3% more per $
STOK
71.2%
-93.1%
CSTE
More free cash flow
STOK
STOK
$178.7M more FCF
STOK
$131.7M
$-47.1M
CSTE

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
CSTE
CSTE
STOK
STOK
Revenue
$94.4M
$158.6M
Net Profit
$-87.9M
$112.9M
Gross Margin
15.5%
Operating Margin
-87.2%
70.2%
Net Margin
-93.1%
71.2%
Revenue YoY
3661.1%
Net Profit YoY
528.0%
EPS (diluted)
$-2.55
$1.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSTE
CSTE
STOK
STOK
Q4 25
$94.4M
Q3 25
$345.4M
Q2 25
$237.7M
Q1 25
$158.6M
Q4 24
$22.6M
Q3 24
$436.7M
Q2 24
$294.3M
Q1 24
$150.6M
Net Profit
CSTE
CSTE
STOK
STOK
Q4 25
$-87.9M
Q3 25
$-18.5M
Q2 25
$-14.3M
Q1 25
$112.9M
Q4 24
$-10.5M
Q3 24
$-57.4M
Q2 24
$-56.6M
Q1 24
$-3.9M
Gross Margin
CSTE
CSTE
STOK
STOK
Q4 25
15.5%
Q3 25
22.5%
Q2 25
23.7%
Q1 25
Q4 24
Q3 24
15.7%
Q2 24
14.1%
Q1 24
19.7%
Operating Margin
CSTE
CSTE
STOK
STOK
Q4 25
-87.2%
Q3 25
-5.5%
Q2 25
-6.2%
Q1 25
70.2%
Q4 24
-60.4%
Q3 24
-12.6%
Q2 24
-18.0%
Q1 24
-3.9%
Net Margin
CSTE
CSTE
STOK
STOK
Q4 25
-93.1%
Q3 25
-5.4%
Q2 25
-6.0%
Q1 25
71.2%
Q4 24
-46.4%
Q3 24
-13.1%
Q2 24
-19.2%
Q1 24
-2.6%
EPS (diluted)
CSTE
CSTE
STOK
STOK
Q4 25
$-2.55
Q3 25
$-0.54
Q2 25
$-0.41
Q1 25
$1.90
Q4 24
$-0.15
Q3 24
$-1.67
Q2 24
$-1.64
Q1 24
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSTE
CSTE
STOK
STOK
Cash + ST InvestmentsLiquidity on hand
$58.4M
$274.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$139.2M
$350.1M
Total Assets
$398.4M
$406.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSTE
CSTE
STOK
STOK
Q4 25
$58.4M
Q3 25
Q2 25
Q1 25
$274.8M
Q4 24
$128.0M
Q3 24
Q2 24
Q1 24
Total Debt
CSTE
CSTE
STOK
STOK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$-12.6M
Stockholders' Equity
CSTE
CSTE
STOK
STOK
Q4 25
$139.2M
Q3 25
$271.6M
Q2 25
$271.6M
Q1 25
$350.1M
Q4 24
$229.0M
Q3 24
$315.1M
Q2 24
$315.1M
Q1 24
$315.1M
Total Assets
CSTE
CSTE
STOK
STOK
Q4 25
$398.4M
Q3 25
$549.0M
Q2 25
$549.0M
Q1 25
$406.9M
Q4 24
$271.6M
Q3 24
$579.9M
Q2 24
$579.9M
Q1 24
$579.9M
Debt / Equity
CSTE
CSTE
STOK
STOK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSTE
CSTE
STOK
STOK
Operating Cash FlowLast quarter
$-38.0M
$131.8M
Free Cash FlowOCF − Capex
$-47.1M
$131.7M
FCF MarginFCF / Revenue
-49.8%
83.0%
Capex IntensityCapex / Revenue
9.6%
0.1%
Cash ConversionOCF / Net Profit
1.17×
TTM Free Cash FlowTrailing 4 quarters
$38.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSTE
CSTE
STOK
STOK
Q4 25
$-38.0M
Q3 25
$35.0M
Q2 25
$18.7M
Q1 25
$131.8M
Q4 24
$-23.2M
Q3 24
$53.3M
Q2 24
$25.1M
Q1 24
$7.9M
Free Cash Flow
CSTE
CSTE
STOK
STOK
Q4 25
$-47.1M
Q3 25
$26.7M
Q2 25
$14.3M
Q1 25
$131.7M
Q4 24
$-23.2M
Q3 24
$44.6M
Q2 24
$20.7M
Q1 24
$5.0M
FCF Margin
CSTE
CSTE
STOK
STOK
Q4 25
-49.8%
Q3 25
7.7%
Q2 25
6.0%
Q1 25
83.0%
Q4 24
-102.7%
Q3 24
10.2%
Q2 24
7.0%
Q1 24
3.3%
Capex Intensity
CSTE
CSTE
STOK
STOK
Q4 25
9.6%
Q3 25
2.4%
Q2 25
1.8%
Q1 25
0.1%
Q4 24
0.2%
Q3 24
2.0%
Q2 24
1.5%
Q1 24
1.9%
Cash Conversion
CSTE
CSTE
STOK
STOK
Q4 25
Q3 25
Q2 25
Q1 25
1.17×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSTE
CSTE

America's$53.0M56%
USA$41.4M44%

STOK
STOK

Segment breakdown not available.

Related Comparisons